Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | ACACB | O00763 | 9/20 | 0.45 |
| ▸ | ACACA | Q13085 | 5/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3545203 | 1.00 | PTPN11 (0.55) | PTPN11NAMPTACACBACACADRD2 | |
| SCHEMBL3542146 | 0.91 | ACACB (0.48) | PTPN11NAMPTACACBACACADRD2 | |
| SCHEMBL3542148 | 0.91 | ACACB (0.48) | PTPN11NAMPTACACBACACADRD2 | |
| SCHEMBL13009671 | 0.90 | NAMPT (0.46) | PTPN11NAMPTACACBACACADRD2 | |
| SCHEMBL13009660 | 0.89 | NAMPT (0.46) | PTPN11NAMPTACACBACACADRD2 | |
| SCHEMBL7283438 | 0.83 | DRD2 (0.50) | ACACBACACADRD2PBKCKS1B | |
| SCHEMBL13009667 | 0.83 | HRH3 (0.52) | NAMPTACACBACACADRD2 | |
| SCHEMBL13009670 | 0.82 | DRD2 (0.49) | ACACBACACADRD2PBKCKS1B | |
| SCHEMBL31206034 | 0.79 | DRD2 (0.44) | NAMPTACACBACACADRD2PBK | |
| SCHEMBL25042017 | 0.76 | DRD2 (0.42) | NAMPTACACBACACADRD2PBK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | PTPN11 3606/4885NAMPT 165/4885ACACB 154/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | PTPN11 3612/4885NAMPT 161/4885ACACB 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.